It has been suggested that medicines are unaffordable in low-income countries and that world manufacturing and trade policies are responsible for high prices. This research investigates medicine prices in urban Mozambique with the objective of understanding how prices are formed and with what public health implications. The study adopts an economic framework and uses a combination of quantitative and qualitative methods to analyse local pharmaceutical prices and markets. The research findings suggest that: (a) local mark-ups are responsible for up to two-thirds of drugs' final prices in private pharmacies; (b) statutory profit and cost ceilings are applied unevenly, due to lack of government control and collusion among suppliers; and (c) the local market appears to respond effectively to the urban population's diverse needs through its low-cost and high-cost segments, although uncertainty around the quality of generics may be inducing consumers to purchase less affordable drugs. We conclude that local markets play a larger than expected role in the determination of prices in Mozambique, and that more research is needed to address the complex issue of affordability of medicines in low-income countries. We also argue that price controls may not be the most effective way to influence access to medicines in low-income countries, and managing demand and supply towards cheaper effective drugs appears a more suitable policy option.
Introduction
The issue of medicine prices is increasingly debated in the fields of health care financing and public health, with unnecessarily high prices assumed to reduce access to essential drugs. Thirty per cent of the world's population is estimated to lack access to essential drugs (WHO 2004a (WHO , 2004b . Drugs are widely believed to be unaffordable in low-income countries, and procurement costs and patents have been considered largely responsible for the high prices (Oxfam 2002; MSF 2005) . Many surveys conducted recently in low-income countries appear to confirm that drugs are scarce in the public sector, unaffordable in private pharmacies, and that local mark-ups add considerably to the burden (Gelders et al. 2006; Health Action International 2006; Babar et al. 2007 ). However, attempts are rarely made to fully understand the determinants and consequences of high pharmaceutical prices in low-income countries from an economic perspective. Some economic commentators have drawn attention to the complexity of measurement and comparison of medicine prices (Danzon and Furukawa 2003) , to the problems of definition of affordability of health care products and services (McPake et al. 1992; Wagstaff and van Doorslaer 2003) , as well as to the difficulties involved in the identification of the market for medical services (Nakamba et al. 2002) . Industrial organization theory also suggests that aspects of industry performance-like drug prices and availability-may be analysed by looking at market structure and players' behaviour (Tirole 1988; Schmalensee and Willig 1989) . Furthermore, although the importance of local markets for distribution and availability of health products is increasingly acknowledged (Goodman et al. 2004) , the influence of local retailing and importing on level of prices has not been fully explored.
In Mozambique, the health system has traditionally been regulated through ministerial decrees by the Ministry of Health under institutionalized influence and input from the medical profession. After its marked orientation towards primary-care principles from the 1970s to the 1990s, public sector regulation has recently allowed a shift towards hospital-based urban services in key areas like human resources development, investment planning and budget allocation. Pharmaceutical policy is one area where non-clinical managerial skills have been applied to help develop regulation on pooling agreements for external funds, rationalization of drugs procurement and distribution, and more recently, on the introduction of AIDS drugs. Attempts to reform the increasingly lucrative private sector have created tension between Ministry of Health officials and the country's new business-oriented elite with political connections. Recent evaluations of the sector and anecdotal evidence suggest that although availability of essential drugs is acceptable in the public sector, price variation is considerable in private pharmacies (Cumbi 2002; Dukes et al. 2003) .
This study adopts a neoclassical economic framework to analyse medicine prices and availability in Mozambique through a combination of quantitative and qualitative methods. First, the context of the country's pharmaceutical market is introduced, and methodologies as well as instruments adopted are explained. Study results on medicine prices, availability and affordability are then presented, followed by the findings on the possible determinants of prices. The paper concludes with a discussion of the results and conclusions.
Background
Mozambique is one of the world's poorest countries and one of the least developed (UNDP 2004 (UNDP , 2006 . After decades of colonial rule, civil war and socialist authoritarian regime, the country started to make the transition to market economy in the 1990s, adopting economic structural adjustment programmes first and then a poverty reduction approach (Hanlon 1996; Government of Mozambique 2006) . Despite its recognized progress in reducing poverty and in achieving Millennium Development Goals (INE 2005; World Bank 2005) , only between 30 and 50% of the population is currently estimated to have access to health care services (Chao and Kostermans 2002; Lindelow et al. 2004) . Although the cost of a minimum package of health services was calculated to be US$34 per capita in 2001 (WHO Commission on Macroeconomics and Health 2001), latest estimates show that in 2003 average health spending in Mozambique was about US$12 per capita, of which US$2 was for drugs (WHO 2004b) . Besides its primary care focus, the pharmaceutical public sector has also been praised for being one of the most effective in Africa (Barker 1983; Folkedal and Kostermans 1997) . Recent evaluations have confirmed the availability of drugs in public facilities and progress made in the development of the regulatory system (Cumbi 2002) .
Until the recent past, medicines import and retail have been led by Medimoc and FARMAC pharmacies, two para-statal enterprises that acted for many years as sole importer and distributor, respectively. Drug imports were officially limited until 1998 by the National Drug Formulary, which was only recently expanded to increase the availability of more sophisticated drugs, most of which can only be obtained through the private sector (Government of Mozambique 1998). The private pharmaceutical sector appears to be developing rapidly in Mozambique's urban areas, filling the availability, quality and diversity gaps left by the public sector. Over 30 importers are currently registered in the country, of which only half are active in the market. Due to the country's economic expansion and the rise of a wealthier middle class, private pharmacies have grown to a noticeable presence-in excess of 200 at the last count, although exclusively in the country's urban areas. Official estimates value the private pharmaceutical sector at around US$16 million per year, although this figure may be an underestimate due to the impact of new and higher priced drugs recently being imported (Ministry of Health 2003; Ministry of Planning & Finance and Ministry of Health 2003) .
The private sector has been regulated by quality, profession and price legislation since the 1990s. Imported medicines are required to be licensed and registered by the Pharmaceutical Department, and are in theory subject to chemical analysis by the National Medicine Quality Control Laboratory. Ministry of Health regulation establishes pharmacy venues and warehousing standards, and pharmacies are subject to random inspection visits by the Ministry of Health Inspection Department.
Pharmaceutical importing and retailing have been liberalized, and the professions are open to national and international operators as long as standards and adequate technical supervision are guaranteed. Prices are regulated through a cost-plus system fixing cost and profit mark-ups for each stage of medicine distribution (Government of Mozambique 1990 Mozambique , 1998 Mozambique , 2003 .
Public pharmacies are located within health centres and hospitals. Drugs are dispensed for a charge of 500MTs (US$0.02) per item in primary care institutions. More substantial co-payments exist for hospital pharmacies, for which a list of recommended selling prices was drawn up in 1998 on the basis of procurement costs, and updated irregularly since then. In private pharmacies expenditures are largely outof-pocket. No public drug reimbursement, insurance or co-payment schemes exist, although a few private companies are beginning to offer their employees full or partial reimbursement for drugs purchased in private pharmacies. A chain of 41 state-owned private pharmacies exists in the country's main urban areas (FARMAC pharmacies). Such outlets are operated according to private sector principles, although they are known to focus predominantly on low-cost generics. The Pharmaceutical Department is the area's main regulatory body, overseen directly by the Minister of Health. It is supported by the Ministry of Health Inspection Department and advised on specific pharmacological issues by the Therapeutic Technical Commission, an unelected body composed of notable physicians from the nearby Maputo Central Hospital. The National Laboratory for Water, Food and Drug Quality Control is officially responsible for sampling and guaranteeing the quality of the medicines traded in the country, although it is widely regarded as an ineffective and under-funded agency.
Due also to media and industry pressure, the sector has recently embarked on the reform of its drug registration system, with the objective of increasing the quality of the drugs imported, expanding the range of drugs available in the country, and ultimately fostering the development of the sector (Government of Mozambique 1999; Chonguica and Durao 2004).
Methods
The purpose of this study is to contribute to the ongoing debate on medicines in low-income countries; understanding the forces influencing drug prices, rather than measuring them, is the main objective. An economic approach was adopted to investigate the pharmaceutical market in Mozambique. Although measuring prices is not the main objective of this paper, a price survey was conducted to obtain a baseline assessment of the current level of prices in the country's main geographical markets. Data from a household survey were used to assess the affordability of drugs; interviews and documentary evidence were used to understand the local market and identify the determinants of prices.
Drawing from economics, the neoclassical structure-conductperformance framework was used to direct qualitative enquiry and interpret findings. This framework proposes that market structure (more or less competitive) directs producers' behaviours (with respect to price and quantity of production decisions), which in turn determines welfare or efficiency. This framework allows for the analysis of the impact of measures such as price controls and regulated barriers to market entry. The research proceeded on the premise that prices and availability of drugs would be determined by market structure (expressed by understandings of the degree of competition, the perceptions of entry barriers and measures of market concentration for example), producers' conduct (such as collusive behaviours) and consumers conduct (such as search behaviours). The economic literature suggested themes and categories to be explained during the interviews, as well as the codes to interpret the interviewees' responses, such as specific aspects of demand and supply of pharmaceuticals, market segmentation, product discrimination and price discrimination (see Supplementary Table 1 in Supplementary data online).
Wholesale and retail prices data were collected for originator/ innovator brands, the most sold and lowest price generics for a basket of 25 drugs in public, private and para-statal (FARMAC) pharmacies (see Table A1 in Annex I). This basket was selected to accord with HAI/WHO lists used for a similar purpose in turn selected on the bases of global burden of disease, importance and availability in low-income countries, and patent status. Unit drug prices were calculated by dividing the drug pack selling price by the number of tables, capsules, vials or doses contained. Those patented versions of the chemical entity first launched on the international market were considered as 'originator' or 'innovator' brands. Those equivalent versions most sold at the pharmacy level were considered as 'most-sold generics', while 'lowest-price generics' were the cheapest version of the chemical entity found in the pharmacies visited. A drug was considered as available when at least one unit of the specified dosage and formulation was found for purchase in the pharmacy visited. Affordability of drugs was evaluated in terms of days of per capita expenditure needed to purchase a full course of treatment for common diseases. Median total expenditures for urban areas were used, as calculated by the 2003 National Household Survey on the basis of consumption and monetary equivalents (INE 2005) .
The survey methods were based on the HAI/WHO Medicine Prices Survey methodology (WHO and HAI 2003) , although some key aspects were substantially modified for a number of reasons. Among these modifications: (a) sampling procedures were modified to accommodate budget and other feasibility constraints; (b) the present research focused exclusively on urban facilities in order to better focus on the role played by the growing private sector in Mozambique; (c) the original basket of drugs was modified to suit the Mozambican context; and (d) a more conservative measure of affordability was chosen because the HAI/WHO methodology uses the minimum salary of a public sector worker as a benchmark, and this appears to be a higher relative figure in the Mozambican context than in others.
These departures from the HAI/WHO methodology limit the value of comparisons with countries in which that methodology was applied, but were unavoidable given the context of the study. Drugs affordability was assessed by comparing drug treatment costs for common diseases with population median daily expenditures as measured by the 2003 National Household Survey in Mozambique (INE 2005) . Potential determinants of prices were explored by interviewing key representatives of pharmacists, pharmaceutical importers and policy makers on aspects of market structure and conduct, as well as by collecting data on import prices, regulation and size of the market.
Data collection
The medicine price survey was rolled out from October 2004 to February 2005, and interviews were held in February 2006 after analysing the survey data, so that the interviews could take account of the findings. Documents and National Household Survey secondary data were collected throughout the duration of the study. The most important cities in the South, Centre and North of Mozambique were selected. Maputo, Beira, Quelimane and Nampula represent the main commercial and administrative hubs of the country, and approximately 20% of the population is located in those areas. The survey's list of drugs was first adapted to the Mozambican context. The pack size and dose strength selected were those recommended by the HAI/WHO methodology for a core of 16 drugs; for the basket's remaining nine medicines the most frequently prescribed formulation in the country was selected for the survey. Data collectors from the local Pharmaceutical department were trained, and the pharmacy sample was selected around the largest hospital pharmacies in the main urban areas in Mozambique. Private pharmacy sampling in Maputo city was stratified between outlets located in the suburbs and those in central Maputo, in order to capture the diversity of private sector retailers in the capital city. The inclusion/exclusion criteria for the sample were the following:
All pharmacies had to belong to the public, FARMAC or private category, and not be in receipt of support from NGOs or other sponsors; All pharmacies had to be currently active; Public pharmacies had to be from the main hospital of reference for the area selected; Private and FARMAC pharmacies had to be located in the proximity of the hospital pharmacy of reference; Within Maputo city, private pharmacies were either located in central Maputo in the proximity of the Maputo Central Hospital, or in the suburbs around other hospitals of reference (Mavalane and José Macamo).
Public sector pharmacies were included only in hospitals because the drugs in the HAI/WHO list were mainly not designated as primary care drugs in Mozambique, and therefore not available at primary level as a matter of policy. Following the HAI/WHO methodology, these were selected in the country's major urban centres. Private and FARMAC pharmacies were then sampled by their proximity to the selected public health facilities. Pharmacy sampling was random and unweighted for population; in one case when an outlet was found closed at the time of the visit, it was replaced by a substitute from a replacement list. A total of 56 facilities were surveyed from a population of 230 eligible pharmacies among public, private and state-owned private outlets (Table 1) .
Data were collected separately by three teams in four locations, cleaned and double entered by the principal investigator. Local procurement costs were collected by invoices and official price application forms (PAF) from the four largest importers in the country.
The interviews were conducted by the principal investigator in the capital city Maputo. The interview sample was purposive, and it was stratified in three groups to include representatives of pharmacists, importers and policy-makers. Within each group, interviewees were selected according to a maximum diversification criterion, in order to capture the views of operators working mostly with generics or brands, in wealthy as well as poor parts of town. After the initial interviews, further key informants were identified with the help of those already interviewed (snowball technique). A total of 21 informants were interviewed from policy makers and market operators dealing with either generics, branded drugs or both (see Table A2 in Annex I). As not all accepted to have their interview audio-recorded, further informants were identified and included until at least five audio-recorded interviews were obtained for each group.
Data analysis
For each medicine, median values from the groups of observations considered were calculated and used to analyse medicine prices and availability. Medicine price ratios (MPR) were constructed for individual as well as for baskets of drugs by relating the median values derived from the survey to an international procurement reference price, as published by Management Sciences for Health (MSH) (MSH and WHO 2004) . The MSH reference prices are the medians of recent procurement or tender prices offered by not-for-profit suppliers to developing countries for multi-source products, and can be considered a useful gold standard for procurement prices in the developing world. Price analysis was carried out at wholesaling and retailing level; availability was only investigated at the pharmacy level. Basket prices were unweighted and analysed per type of drug, type of pharmacy, and geographical location (see limitations of the methodology in the discussion section).
With the aim of identifying the impact on overall prices of particularly expensive medicines for specific diseases, MPR were also compared across different disease baskets of drugs. The disease groups considered for such cross-basket comparisons were: (a) antibacterials and antibiotics, including Amoxicilline, Amoxicilline and Clavulanic, Ciprofloxacine, Cotrimoxazole; (b) antihyperthensives, inclusive of Atenolol, Captopril, Hydrochlortiazide, Metildopa and Nifedipine; (c) psychotropics, including Amytriptline, Diazepam, Fluoxetine and Flufenazine.
Percentile analysis was used to investigate within-sample variation. Pair-wise price and availability correlation was examined to explore the association between groups of drugs and pharmacies. The WHO survey workbook, a purposedesigned database, and the statistical software SPSS were used to store data and perform analysis. Population expenditure data and drug treatment costs (estimated total price of a course of treatment) were used to assess medicine affordability. National Household Survey expenditure and demographic data were used to identify median daily expenditures (MDE) per capita for the urban population. National Household Survey data were analysed through STATA statistical software to calculate median daily expenditures, as well as quintiles, deciles and centiles of the population distribution.
Drawing from the neoclassical Structure Conduct Performance model, a set of hypotheses was elaborated to identify possible determinants of high drug prices and selective availability in Mozambique. Open-ended questions were posed to interviewees to explore themes such as market entry barriers, market conduct and monopolistic behaviour. Interviews were audio-recorded, transcribed and coded in Portuguese; relevant quotes and passages were then translated into English. Content analysis was used to identify themes and categories. The majority of the codes used for the analysis of interview' contents were concepts identified from economic theory on markets, price equilibrium, affordability and regulation. In a number of cases, indigenous concepts were identified in the transcripts and contributed to the definition of codes to investigate. Quotes were grouped by codes and areas, leading to identification of categories, patterns and themes (Patton 2002) . Deviant cases were examined to test and corroborate specific interpretations.
Results

Availability of medicines
The results from the price survey showed that the market is dominated by generics, with originator brands found available in only 3% of cases in private pharmacies. The median availability of generics was 60% in the public sector, and 73.5% in private pharmacies. FARMAC pharmacies recorded the highest availability rate (77.8%), with little variation across outlets (Table 2) .
Availability of drugs in the public pharmacies visited was considerably higher in Maputo City (75%) than in the rest of the country (50%). In private pharmacies, generics were found to be 20-28% less available outside the capital city. Central Maputo outlets were found to have a 100% median availability of generics. For those pharmacies located in the city suburbs, generics were found to be available in 80% of cases. Both types of private pharmacies appeared to keep in stock only a limited range of brands (less than 3%), although availability of Cotrimoxazole, Amoxicillin, Nifedipide and Metformin was found to be consistently high (see Table A3 in Annex I).
Price of medicines
Among the pharmacies sampled, retail prices for generics were cheaper than the MSH reference price in public urban pharmacies, and between 4 and 5 times the MSH reference in the other sectors. Originator brands were 23 and 5 times the same reference price in private pharmacies and in FARMACs, respectively, although in the latter they were only found sporadically. Price differences between types of pharmacy were statistically significant (P < 0.05) with the exception of the MPR for brands in private and FARMAC outlets (P < 0.13), due to its large variation and the small sample (Table 3) . Among generics, the vast majority of drugs were found to have an MPR lower than 10. Among originator brands, at least four drugs were above 50 times the international standard. Fluconazole and Glibenclamide were the products with the highest MPR (236 and 73, respectively).
In the public sector, although the prices recorded were largely below the MSH reference price, generics were found to be more expensive outside Maputo (MPR 0.68) than in the capital city (MPR 0.31). In private pharmacies, drugs were found to be in general more expensive in Maputo than in other urban areas of the country. This difference was particularly acute for brands, which in Maputo were twice as expensive as in the rest of the Note: Availability of the most-sold and lowest-price generics are identical, as the two concepts overlapped in the field unless distinct generic versions were found in stock for the same drug in the pharmacies visited. *n represents the number of products on which the analysis was performed (those found available at least four times).
country, although available only in a small minority of cases (Table 4) . Within FARMAC pharmacies, most-sold generics were 23% more expensive, and lowest-price generics 8% more expensive, in Maputo than in the rest of the country. Within Maputo City, those private pharmacies located in wealthy parts of town were found to have prices significantly higher than those in city suburbs. The largest variations were recorded for most-sold generics, which in Central Maputo outlets were more than twice as expensive as in pharmacies in the suburbs, and were sold at a price similar to that for original drugs. Price variations across drug types were significant in private pharmacies; for those medicines available in both brand and generic versions, the former were found to be on average 4-5 times more expensive than the latter. Price variation within the same product class was found to be significant among originator brands (minimum MPR 7.90 -maximum MPR 59.42). In FARMAC pharmacies, price variations within the same product class were recorded for brands (minimum MPR 4.15 -maximum MPR 19.79), but not for generics.
When looking at those drugs found in all three sectors in their lowest-price version, prices in the public sector were always lower than those in private and FARMAC pharmacies. In the case of Glibenclamide in private pharmacies, the price was 90 times that of public pharmacies, and 3 times that of FARMAC (Figure 1) . In private pharmacies, high prices to consumers appeared driven by high procurement costs (as for Glibenclamide and Hydrochlorothiazide), with the exception of Aciclovir for which a high MPR was recorded despite its low procurement cost. The level of FARMAC prices for low-cost generics was in general between those of public and private pharmacies, and had little relationship with procurement cost.
In the case of Hydrochlorotiazide, the FARMAC MPR was higher than the private one, and 14 times the procurement cost.
Lowest-price generics usually were the most-sold versions of any drug, with the exception of Aciclovir, for which a slightly more expensive branded generic was its most-sold version (MPR 8.63 ). Brands were always several times the price of generics; for Glibenclamide, the original brand was found in 13 private pharmacies with an MPR of 73.1. Also its procurement price was found to be relatively high (30.26).
When comparing prices across different disease baskets, MPR patterns did not change substantially in comparison with the price patterns from the general basket of 25 drugs (Table 5 ). Main differences were that: (1) MPRs for anti-infectives were generally lower, except for brand procurement; (2) antihypertensives also had lower MPRs, except for brands in private and FARMAC pharmacies, and; (3) psychotropics were only available in their generic versions, and had higher MPRs in private pharmacies, but lower MPRs than other drugs in FARMACs.
The price variation in private pharmacies was the largest amongst brands (where the first quartile of drugs arranged by MPR had an MPR of 7.90, and the last quartile had an MPR of 59.42), and smallest among low-price generics (first quartile MPR 3.59; last 8.37) (see Table A5 in Annex I). The same price pattern was observed across all baskets of drugs, although price variability was recorded to be low for antibacterial most-sold 
(1) (7) (7)
(1) (8) (7) (23) Figure 1 Lowest-price generics' median price ratio (MPR) for selected drugs (number of observations in parentheses) 
Affordability of drugs
In order to measure the affordability of selected drugs in the country, the median per capita daily expenditure was calculated as the median value of total household consumption divided by the mean number of household members for urban areas in Mozambique (INE 2005) . Lowest-price generics bought in public sector pharmacies were most affordable. In private and FARMAC outlets, the price of treatment with the same kind of drugs was on average 10 times that in the public sector. Table 6 shows the cost of a full course of treatment with lowest-price generics in terms of median daily expenditure for a range of conditions. Long-term treatments for chronic conditions like asthma, diabetes, epilepsy, hypertension, peptic ulcer and psychiatric disorders were less affordable than treatments for acute conditions across the three sectors. Treatment with branded drugs in private pharmacies never cost below 10 median daily expenditure units. The comparison of these treatment costs with the national expenditure distribution suggested that only a small fraction of the urban population would be able to purchase brand drugs in private pharmacies even on the basis of total daily expenditure. In public pharmacies, one median daily expenditure unit was found to be sufficient to cover the cost of all treatments with the exception of peptic ulcer. In private and FARMAC pharmacies, between 2 and 14 median daily expenditure units were required to buy lowest-price generics for the treatments considered, except for treatment of gonorrhoea which required no more than 0.2 median daily expenditure units in any type of pharmacy.
Determinants of price
Pharmaceutical prices are regulated by a 1990 ministerial decree, fixing the same maximum percentage mark-up for all drugs for each stage of the distribution, based on a drugs 'free on board' (FOB) price (the price at the point of manufacture) and the cost, insurance and freight (CIF) total. Insurance and freight costs are not to exceed 13% of the FOB; wholesaling costs 3% of the CIF; wholesaler's profit 9% of the CIF; and retailer's profit 72.5% of the CIF price (Table 7) . No government tax is applied along the supply-chain. Importers are always required to stamp the final price to consumers on the drug packs sold to pharmacies, and to act also as wholesalers, with the stated objective of avoiding proliferation of intermediary agents (Government of Mozambique 1990).
In the following section our analysis focuses on the impact of distribution mark-ups on retail prices. According to the above statutory mark-ups, importer margins (CIF, warehousing, distribution and profit) would account for approximately 19.14% of the final price to consumers, with pharmacists' profit margin determining 37.44% of a medicine's final price. Therefore, procurement costs would be identified as the main determinant of drug prices in Mozambique, representing 43.42% of final prices to consumers. However, in the Mozambique study, a considerable gap emerges between procurement costs as reported by official price application documents, and prices to consumers found by the survey in private pharmacies (Table 8 ). The combined analysis of these two sets of data suggests that procurement prices would represent only 22% of generic and 38% of originator final prices, and that local margins (insurance and freight, distribution, importer and retailers margins) would then be responsible for over two-thirds of drug prices. On the other hand, higher than allowed mark-ups early in the distribution chain would compound the final MPR, even if the permitted retailer's profit margin is applied.
Although the law explicitly fixes profit mark-ups rather than maximum margin allowed, reports from interviews confirmed that pharmacists often adjust mark-ups to the demand for specific products, and that importers negotiate procurement costs with international distributors. Direct observation and interviews alike also confirmed that the statutory practice of stamping the final price to the consumer on the medicine package has been widely abandoned.
''In our system, it is possible to negotiate the price with the manufacturer. I can calculate the profit I want to make, and decide at what price I want to buy the drug in Portugal. Then I negotiate the value of the invoice with the manufacturer. At the end it is no competition price. It is agreed.'' (Policy-maker from Ministry of Health) ''When the product does not sell, I decrease the price. I am not going to see the product run on its expiry date. I have to at least cover its The analysis of several price application and importation documents also showed that arbitrary mark-ups, such as devaluation and warehousing costs and market adjustment factors, are sometimes introduced by importers to inflate prices to retailers, and that mark-up percentages were found often diverging from those established by the law.
The market boundaries for any given product may go beyond administrative and geographic borders (Stigler and Sherwin 1985; Zwanzinger et al. 1994) . In Mozambique, the demand for drugs was described by all the interviewees as geographically divided between the capital city area and the rest of the country, with the former including Maputo City and Maputo Province but also pharmacies from neighbouring Mpumalanga region in South Africa. Central Maputo market appeared to identify a limited number of luxury pharmacies catering for affluent clients who often go to neighbouring South Africa to buy their health care products. Consumers reported shopping in private pharmacies to avoid waiting times at overcrowded public hospitals, but also because of the perceived higher quality of the facilities.
Economic theory suggests that barriers to entry and concentration of supply could induce prices higher than normal (Bain 1956; Donsimoni et al. 1984) . Pharmaceutical retailing was not reported to be dominated by any specific pharmacy group, as the market volume is fragmented among over 210 outlets. However, it has to be noted that FARMAC holds one-sixth of the total number of private pharmacies nationwide, and that successful vertical integrated businesses are beginning to emerge. The current pharmaceutical regulation was regarded by private operators as making retailing lucrative and importing unattractive for new operators. According to the law, the prerequisite to open a pharmacy is that supervision of a pharmaceutical technician be provided, and the statutory profit mark-up is generous (76.3% on CIF price, which translates into a 60% margin on wholesaling price). For importers, the current regulation establishes the legal obligation to operate as both importer and wholesaler, and fixes lower profit margins (12.5% on the importing price).
Economic theory also suggests that suppliers may gain market power and charge higher prices through collusion, market segmentation and price discrimination. A few pieces of evidence suggest that collusion may exist among suppliers in this market: (a) importers and pharmacists are organized into nationality-based groups trading on drugs from either India or Portugal; (b) vertical integration between producers abroad and local importers and retailers was reported to be the most profitable way to operate in the market; and (c) little compliance with official price regulation was observed at all stages of the pharmaceutical distribution chain.
Segmentation of the market can be welfare-enhancing, as it allows suppliers to disaggregate the demand into segments of potential customers with similar characteristics, and to charge according to the ability and willingness-to pay of each (Smith 1956) . In this respect, Ramsey's research showed that prices may reflect consumer's willingness to pay as measured by elasticity of demand (Ramsey 1927) . However, market segmentation also results in price discrimination, and enables providers to extract consumers' surplus (Stigler 1963) . From all the interviews, it emerged that, at least in Maputo, the market is perceived as divided into a low-cost segment and a high-cost one, and similar drugs appeared to be sold at a premium in the latter segment (see Table 4 ). Segmentation appears to take place along the lines of customer types, product quality, type of supplier, as well as pharmacy location and physical characteristics. Pharmacists and importers described dividing their clientele into população (the lower class population) from the bairro (suburb), of limited willingness to pay, and the more affluent Mozambican elite and expatriates, with a preference for branded medicines. Low-cost medicines are generally referred to as Indian or Asian generics, distinguished from expensive originator brands and branded generics, which are generally associated with Portuguese and European manufacturers. Importers are described as divided into those of Portuguese or South African nationality, and Indians, while retailers in Maputo divide themselves into low-cost bairro pharmacies located in the suburbs, and expensive Central Maputo pharmacies from the wealthy parts of town. ''We work exclusively with brands. We do not trade on generics. We also have products that currently do not exist in the market. Our business strategy is to bring to the market products for which there are currently gaps in supply. This is why I maintain that we do not regard other operators as competitors, but rather as business partners''. (Importer of brand drugs) ''(. . .) In those pharmacies in the bairro one cannot stock brands, as they are too expensive. So one will have to go and procure cheaper drugs. But if the pharmacy is here, in the city, one will not be interested in stocking cheaper drugs. But, if one is there, close to the população, there he will have to put cheaper drugs''.
(Policy-maker from Ministry of Health)
Elements of product differentiation were also observed at all levels, defined as the extent to which consumers distinguish and have preference between competing products (Hotelling 1929) . From the interviews it emerged that customers in Maputo are mostly influenced by prescribers and pharmacists, but also by quality signals like product origin, package and outlet appearance. No hard evidence was found that generics are truly of inferior quality, as no laboratory capacity exists in the country to test the imported drugs' chemical composition. Nonetheless, the vast majority of market operators appeared to contribute to reinforce the conviction that quality differences do exist between expensive branded products and cheaper generics.
''In the bairro they do not ask whether [the drug] is Indian or not. What they really want is blisters. They think that blistered drugs cannot be fakes. (. . .) they think that, as those drugs have an expiry date, they cannot be counterfeited. If they are counterfeited, it must have been there in the country of origin, but the Ministry of Health certified the date is true, and they believe''. (Pharmacist from the suburbs) ''I am convinced that many products from India and China are low quality here (. . .), but people make generalizations and think that all generics are bad''. (Policy-maker from Ministry of Health)
Discussion
The study findings suggest that in Mozambique local margins are the main determinant of drug prices in the private sector, and that procurement costs only account for one-third of prices to consumers. Results from the pharmacies surveyed also suggest that more affordable generics can be found in urban areas in public, private and FARMAC pharmacies, alongside the expensive brands offered by luxury retailers in wealthy parts of Maputo city. The comparability of the survey results with similar studies in other low-income countries is limited, due to differences in sampling methodology, measures of affordability and the basket of drugs selected. However, these results from Mozambique appear broadly consistent with those of surveys from other countries (Health Action International 2006; Babar et al. 2007) . For a number of reasons the research findings need to be interpreted with a degree of caution:
The results are not generalizable to the whole country, since the research only focused on urban areas in Mozambique.
The survey used a different sampling strategy than the WHO/HAI methodology and differed in other respects. These differences imply that the approach was not validated by large-scale studies and that results are not reliably comparable to those obtained using the WHO/HAI methodology elsewhere. The use of central tendencies for a basket of drugs lends itself to criticism, as it critically depends on the drugs included and on those found available. Our choice of median daily expenditures may be contested as the most appropriate measure of affordability. An absolute measure of availability of drugs was adopted, which was not related to any desired level of stock nor to level of need. The findings related to procurement costs are based on a limited number of price application and import authorization documents. Marked changes in the Ministry of Health political leadership after 2004, as well as the related attempts to reform the sector, may have had an impact on the sector that would not be captured by the present study.
Despite these limitations, it appears safe to argue that the commonly held belief that all drugs are unaffordable in lowincome countries because of high import costs is a somewhat crude generalization. A more nuanced insight seems to be needed into the affordability of medicines and into how local markets, which appear to play an important role in the determination of medicine prices, respond to demand in lowincome countries.
It seems that the market power created by suppliers' collusion, market segmentation and product differentiation strategies enables importers and retailers to make abnormal profits and bypass the existing price regulation. Some interviewees alleged that regulators in the 1990s had a vested interest in guaranteeing a generous mark-up to the pharmacists. However, by setting low profit margins for importers, the current regulation also appears to favour market operators who have special connections with local institutions capable of blurring the boundaries between wholesale and retail markets, thus creating an informal barrier to entry for new importers from generic producing countries. Uncertainty around the quality of some generics lends credibility to the product differentiation strategy used by importers and especially retailers, thus signalling to consumers to select less affordable branded drugs.
The current pharmaceutical price regulation appears to be disregarded in Mozambique. There is evidence that importers collude with foreign suppliers to misreport procurement prices, and with retailers not to apply statutory margins. Pharmacists also reported adjusting final prices according to market demand. These findings appear consistent with the body of economic literature which maintains that price controls are not effective policy tools, especially in developing countries (Hongoro and Kumaranayake 2000; Kumaranayake et al. 2003) . However, they differ from classical public health recommendations on how to contain drug expenditures in industrialized countries as well as in low-income countries (Jacobzone 2000; Sweeny 2004) , and from the consolidated practice of pharmaceutical regulation worldwide and in neighbouring countries (Everard 2003; Mossialos et al. 2004; Ministry of Health, South Africa 2005) . The evidence gathered on compliance with price regulation in Mozambique is admittedly only circumstantial, as it was beyond the scope of this study to demonstrate violation of the law. Nonetheless, it appears improbable that altering profit mark-ups would be an effective policy option to reduce drug prices in Mozambique, as new margins would be equally likely to be disregarded.
We conclude that affordable generics can be available in urban areas, but that they may not get selected because of prescriber and patient perceptions of uncertainty around their quality and because of suppliers' marketing strategies. Governments could take an active role in influencing demand and supply towards cheaper medicine options while taking measures to assure their quality and to re-establish their credibility. In the longer run, the Ministry of Health's capacity to screen for poor quality drugs could be developed in order to support the foundations of a market able to regulate itself. In the shorter run, the literature suggests a number of supplyside as well as demand-side policy measures aimed at encouraging the consumption of one specific product over another, such as taxation, subsidies and differential profit incentives for health professionals (Huttin 1996; Ensor and Cooper 2004; Mossialos and Srivastava 2008) . Ensor and Weinzierl (2006) suggest that compulsory disclosure of product information that can be used by consumers to make informed market decisions is the least expensive and interventionist of regulation mechanisms. Government and generics importers could also invest in publicity measures, such as radio and newspaper messages, to promote generics of established quality. This would induce people to use quality signals other than the brand of the products in the market. Given their public ownership, wide presence on the ground and sound management, FARMAC pharmacies also look wellpositioned to influence at least the low-cost segment of the market towards cheaper generics, according to what has been described in the literature as a model of 'regulation by participation' (Harris and Weins 1980; Sertel 1988; DeFraja and DelBono 1989) . However, substantial investment in its worn-out physical infrastructure would be needed to give FARMAC greater credibility in supporting a government policy to promote affordable generics at all levels.
Conclusions
The present research contributes in a number of ways to the existing debate on medicine prices in low-income countries. It shows the importance of understanding local markets regarding access to medicines, as local margins can be at least as important as manufacturers' prices for the determination of medicine prices. The research also suggests that the belief that drugs are unaffordable in low-income countries may be over-simplified for urban areas if those of Mozambique are typical, and that pharmaceutical markets, structured in segments, can respond to the needs of different sections of the population. Another key point is that price controls do not appear to be an effective measure to contain medicine prices in an environment lacking enforcement capacity, and that managing both demand and supply conditions for drugs may represent a more effective option.
We believe that a different body of knowledge and further research is required to fully explore the implications of these conclusions. The area of medicine markets in low-income countries appears noticeably under-researched, perhaps because of the assumption that the responsibility for high prices lies predominantly with drug manufacturers. Industrial economics studies of local pharmaceutical sectors would help to understand the dynamics of such markets in low-income countries, suggest approaches to improve their performance and the scope for government intervention. Furthermore, a better understanding of consumers' perceptions of generics would inform attempts to address barriers to the popularization of such drugs, as well as raise the profile of demand factors in the design of policies to expand access to medicines. Amoxicillin and clavulanic acid 
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